Exec Chat: Intuitive Surgical CEO Gary Guthart On Expansion, Innovation And Competition

With the opening of a new UK & Ireland headquarters last month, Intuitive Surgical is aiming to strengthen its grip on the the market as it faces increasing competition in the robotic surgery space. CEO Gary Guthart sat down with Medtech Insight at its new Oxfordshire, UK HQ to discuss expansion and innovation plans.

Interview

With medical device companies seizing the opportunity to move into robotic surgery, market leader Intuitive Surgical is facing intense competition. The California-based company has dominated the field for over 20 years but with the opening of a new UK and Ireland HQ, (Also see "Intuitive Surgical Opens New UK/Ireland HQ In Oxfordshire" - Medtech Insight, 4 September, 2019.) it has no plans to surrender to competition. Medtech Insight chats with CEO Gary Guthart, a California native who has been with the company since its inception in 1996 and served as CEO since 2010.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

OneCell Diagnostics – Now 1Cell.Ai - Launches Multi-Modal Cancer Diagnostic Panel OncoIncytes

 

OneCell Diagnostics, the Mumbai-based startup backed with $16m in series A funding, is rebranding to 1Cell.Ai to represent the firm's focus on combining deep science with AI-powered capabilities.

Edwards Mitral Valve Replacement System SAPIEN M3 Receives CE Mark

 

“We believe [the SAPIEN M3] launch alongside PASCAL and EVOQUE will help support the company’s target of $2bn in transcatheter mitral and tricuspid therapies sales by 2030,” noted analysts from Leerink Partners.

Diagnostics Are Essential, But How Can Companies Ensure A Fair Price?

 

Biotech and pharma are increasingly clear about one thing: They need diagnostics. But with prices suppressed, how have diagnostics companies proven their utility without going under?

Enovis Appoints Damien McDonald CEO, Reaffirms Q1 Guidance Amid Strategic Growth Push

 
• By 

Enovis has named veteran medtech leader Damien McDonald as its new CEO effective 12 May as the orthopedic company reaffirms first-quarter 2025 revenue guidance of between $555m and $563m. Medtech Insight spoke with Tim Czartoski, Enovis’ president of US surgical and global product and enabling technologies, about the firm’s growth strategy and innovation plans.

More from Business